SCHEDULE: Vanguard Group Reports 0% Enovix Stake Post-Realignment

The Vanguard Group reported a 0% beneficial ownership in Enovix Corp following an internal realignment, with subsidiaries now reporting holdings separately.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Enovix Corp, indicating a 0% beneficial ownership of its common stock.
• This change is a direct result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis), in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Enovix Corp.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update from The Vanguard Group regarding its internal reporting structure, with no direct positive or negative implications for Enovix Corp's operational performance or financial health.

Positives

• The filing provides clarity on The Vanguard Group's current beneficial ownership status, reflecting a transparent reporting process following an internal corporate realignment.

Negatives

• The Vanguard Group, as the parent entity, no longer reports a direct beneficial ownership stake in Enovix Corp, which might be perceived as a reduction in direct institutional interest from the parent organization.

Risks

• The disaggregation of reporting by Vanguard's subsidiaries means that the parent entity no longer directly holds or reports beneficial ownership, potentially making it less straightforward to track the aggregate holdings of the broader Vanguard ecosystem in Enovix Corp from this specific filing.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Enovix Corp's future performance or The Vanguard Group's future investment intentions beyond the current reporting structure.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large institutional investors like The Vanguard Group to adjust their internal reporting structures, particularly for compliance with SEC regulations. While The Vanguard Group itself no longer reports direct beneficial ownership, its subsidiaries may continue to hold stakes in Enovix Corp, aligning with broader trends of diversified asset management across various funds and divisions.

Comparison to Industry Standards

• The disaggregated reporting approach by The Vanguard Group aligns with SEC Release No. 34-39538, a standard practice for large investment advisers managing numerous funds and accounts.
• This internal realignment is a common operational adjustment for large asset managers to streamline compliance and reporting for their various investment vehicles.

Stakeholder Impact

• Shareholders (Enovix Corp): May observe a change in reported institutional ownership from The Vanguard Group, though underlying holdings by Vanguard's subsidiaries may persist. The direct impact on share price is likely minimal as it's an administrative change.
• Investors (Vanguard Funds): The internal realignment aims to streamline reporting, potentially improving transparency for investors in Vanguard's various funds.

Next Steps

• Future beneficial ownership filings related to Enovix Corp from Vanguard's subsidiaries or business divisions will be reported separately.

Key Dates

Keywords

Enovix Corp, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Investment Adviser, Corporate Realignment